Monitoring of NOACs with TEG6S
Ramin Artang, MD, discusses a University of Nebraska Medical Center study aimed at improving monitoring of NOACs. NOACs were initially thought to not require monitoring, however the practice of anticoagulating a patient requires some level of monitoring to ensure therapy is not only safe but is also effective. Evaluating outcomes alone in an anticoagulated patient is insufficient, particularly when the patient is having or could have an adverse event. There are many commercial approaches to monitoring NOACs, with the newest technology being TEG6S. The advantage of TEG6S is primarily that it is a point-of-care assay. With this assay, a clinician can know within 10 minutes whether a patient is in the sub- or supra- therapeutic range with a NOAC drug.